We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer (PBH) Up on Q3 Earnings Beat & Raised View
Read MoreHide Full Article
Prestige Consumer Healthcare Inc. (PBH - Free Report) reported third-quarter fiscal 2020 results, with both top and bottom lines surpassing the Zacks Consensus Estimate for the fourth straight time on a combined basis. Earnings also improved year on year. Based on its strong year-to-date results and efficient use of cash flows, management raised its earnings outlook for fiscal 2020.
Shares of the company gained 8.4% in yesterday’s trading session. Further, this Zacks Rank #3 (Hold) stock has gained 18.2% in the past three months compared with the industry’s growth of 1%.
Q3 Details
The company posted adjusted earnings of 81 cents per share, which surpassed the Zacks Consensus Estimate of 75 cents. This marked its eighth consecutive quarter of earnings beat. Quarterly earnings also improved almost 11% year over year.
Prestige Consumer Healthcare Inc. Price and EPS Surprise
Total revenues came in at $241.6 million compared with the Zacks Consensus Estimate of $241 million and the year-ago period’s figure of $241.4 million. Organic revenues inched up 0.5% (excluding currency effects). Top-line results were backed by robust consumption trends at core brands in the domestic regions and solid international unit performance. This was partly offset by persistent retailer inventory reductions.
Adjusted gross profit came in at $140.1 million, which inched up 0.6% from the prior-year quarter’s figure. Adjusted gross margin expanded slightly to 58%.
Adjusted EBITDA was $86.9 million, up 2% year over year. Adjusted EBITDA margin expanded 70 bps to 36%.
Segment Performance
Revenues in the North American OTC Healthcare segment were $214.9 million, down 0.9% year over year. The decline is accountable to retailer inventory reductions, compensated by increased consumption at core categories.
Revenues in the International OTC Healthcare segment totaled $26.7 million, up about 8% from the year-ago quarter’s figure. The upside can be attributed to increased consumption and shipments in the Asia Pacific and Australia, which were partly negated by currency headwinds to the tune of $1 million.
Financial Updates
The company exited the quarter under review with cash and cash equivalents of $28.6 million, long-term debt (net) of $1,701.3 million and total shareholders’ equity of $1,156.5 million.
Net cash provided by operating activities in the reported quarter was $58 million. Adjusted free cash flow for the quarter amounted to $56.3 million.
As of Dec 31, 2019, the company’s net debt position was about $1.7 billion.
Outlook
For fiscal 2020, the company still anticipates revenues of $947-$957 million. Organic revenues are expected to stay flat.
Adjusted earnings are now envisioned in the range of $2.85-$2.87 per share, up from the prior view of $2.76-$2.83.
Adjusted free cash flow is forecasted to be $200 million or more in fiscal 2020.
Looking for Consumer Discretionary Picks? Check These
G-III Apparel (GIII - Free Report) , with a Zacks Rank #2 (Buy), also has a robust earnings surprise record.
Guess? (GES - Free Report) has a long-term earnings growth rate of 17.5% and a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Prestige Consumer (PBH) Up on Q3 Earnings Beat & Raised View
Prestige Consumer Healthcare Inc. (PBH - Free Report) reported third-quarter fiscal 2020 results, with both top and bottom lines surpassing the Zacks Consensus Estimate for the fourth straight time on a combined basis. Earnings also improved year on year. Based on its strong year-to-date results and efficient use of cash flows, management raised its earnings outlook for fiscal 2020.
Shares of the company gained 8.4% in yesterday’s trading session. Further, this Zacks Rank #3 (Hold) stock has gained 18.2% in the past three months compared with the industry’s growth of 1%.
Q3 Details
The company posted adjusted earnings of 81 cents per share, which surpassed the Zacks Consensus Estimate of 75 cents. This marked its eighth consecutive quarter of earnings beat. Quarterly earnings also improved almost 11% year over year.
Prestige Consumer Healthcare Inc. Price and EPS Surprise
Prestige Consumer Healthcare Inc. price-eps-surprise | Prestige Consumer Healthcare Inc. Quote
Total revenues came in at $241.6 million compared with the Zacks Consensus Estimate of $241 million and the year-ago period’s figure of $241.4 million. Organic revenues inched up 0.5% (excluding currency effects). Top-line results were backed by robust consumption trends at core brands in the domestic regions and solid international unit performance. This was partly offset by persistent retailer inventory reductions.
Adjusted gross profit came in at $140.1 million, which inched up 0.6% from the prior-year quarter’s figure. Adjusted gross margin expanded slightly to 58%.
Adjusted EBITDA was $86.9 million, up 2% year over year. Adjusted EBITDA margin expanded 70 bps to 36%.
Segment Performance
Revenues in the North American OTC Healthcare segment were $214.9 million, down 0.9% year over year. The decline is accountable to retailer inventory reductions, compensated by increased consumption at core categories.
Revenues in the International OTC Healthcare segment totaled $26.7 million, up about 8% from the year-ago quarter’s figure. The upside can be attributed to increased consumption and shipments in the Asia Pacific and Australia, which were partly negated by currency headwinds to the tune of $1 million.
Financial Updates
The company exited the quarter under review with cash and cash equivalents of $28.6 million, long-term debt (net) of $1,701.3 million and total shareholders’ equity of $1,156.5 million.
Net cash provided by operating activities in the reported quarter was $58 million. Adjusted free cash flow for the quarter amounted to $56.3 million.
As of Dec 31, 2019, the company’s net debt position was about $1.7 billion.
Outlook
For fiscal 2020, the company still anticipates revenues of $947-$957 million. Organic revenues are expected to stay flat.
Adjusted earnings are now envisioned in the range of $2.85-$2.87 per share, up from the prior view of $2.76-$2.83.
Adjusted free cash flow is forecasted to be $200 million or more in fiscal 2020.
Looking for Consumer Discretionary Picks? Check These
Ralph Lauren (RL - Free Report) , with a Zacks Rank #1 (Strong Buy), has an impressive earnings surprise record. You can see the complete list of today’s Zacks #1 Rank stocks here.
G-III Apparel (GIII - Free Report) , with a Zacks Rank #2 (Buy), also has a robust earnings surprise record.
Guess? (GES - Free Report) has a long-term earnings growth rate of 17.5% and a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>